Cardiovascular safety of fixed-dose extended-release naltrexone/bupropion in clinical practice.

ABSTRACT:

Background

The fixed-dose extended-release combination of naltrexone/bupropion (NB-ER) is indicated to treat overweight and obesity in adults as an adjunct to a reduced-calorie diet and increased physical activity. This study compared the rate of major adverse cardiovascular events (MACE) and its components (nonfatal acute myocardial infarction [AMI], nonfatal stroke, and cardiovascular death) between patients initiating NB-ER and those initiating lorcaserin (removed from US market in 2020; included as active comparator to minimize possible confounding by indication) in routine clinical practice.

Methods

This was a retrospective cohort study with a new-user, active-comparator design. Patients initiating NB-ER or lorcaserin were identified using Arcadia Data Research electron

SUBMITTER: Kyle M 

PROVIDER: S-EPMC11919370 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature